Finance

Lists
Q3 2026 earnings ā€¢ released ā€¢ EPS miss -4.86%
See results
SANA:NASDAQ
Sana Biotechnology Inc
$2.37
+1.28%
(+0.030) 1D
$2.36
-0.42% (-0.0100)
After hours
Closed: Nov 6, 4:00:00ā€ÆPM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SANA...
Open
$2.49
High
$2.49
Low
$2.28
Mkt. cap
709.48M
Avg. vol.
3.05M
Volume
2.31M
52-wk high
$5.49
52-wk low
$2.22
EPS
-$0.76
Beta
2.30
Shares outstanding
299.36M
No. of employees
142
Open
$2.49
High
$2.49
Low
$2.28
Mkt. cap
709.48M
Avg. vol.
3.05M
Volume
2.31M
52-wk high
$5.49
52-wk low
$2.22
EPS
-$0.76
Beta
2.30
Shares outstanding
299.36M
No. of employees
142
News stories
From web sources and news partners
About Sana Biotechnology Inc
CEOSteve Harr
Employees142
Founded2018
HeadquartersSeattle, Washington, United States
SectorHealth Care
IndustryBiotechnology
Websitesana.com
Analyst ratings
Based on 5 analysts giving stock ratings to SANA in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for SANA in the last 3 months.
Highest
Current $2.37
$12.00 (+406.33%)
Average
$8.00 (+237.55%)
Lowest
$6.00 (+153.16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$6.00
+153.2%
11/06/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$7.00
+195.4%
09/21/2026
Maxwell Skor
Morgan Stanley
Buy
Reiterated
$12.00
+406.3%
08/17/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/11/2026
Martin Fan
Wedbush
Buy
Reiterated
$7.00
+195.4%
08/11/2026
Michael King
Rodman & Renshaw
Buy
Initiated
$16.00
+575.1%
05/11/2026
Samantha Semenkow
Citi
Buy
Maintained
$12.00
+406.3%
03/04/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-$0.14 / -$0.13
-4.86%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
35.22M
40.44M
26.41M
38.28M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.28M
12.19M
11.46M
10.78M
Operating expense
45.51M
52.62M
37.87M
49.06M
Total operating expenses
45.51M
52.62M
37.87M
49.06M
Operating income
-45.51M
-52.62M
-37.87M
-49.06M
Other non operating income
360.00K
3.40M
453.00K
656.00K
EBT including unusual items
-42.15M
-58.82M
-47.21M
-63.64M
EBT excluding unusual items
-44.14M
-47.95M
-36.46M
-47.27M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-42.15M
-58.82M
-47.21M
-63.64M
Net profit margin
-
-
-
-
Earnings per share
-0.15
-0.16
-0.14
-0.13
Interest and investment income
1.00M
1.28M
951.00K
1.13M
Interest expense
-
-
-
-
Net interest expenses
1.00M
1.28M
951.00K
1.13M
Depreciation and amortization charges
-
-
-
-
EBITDA
-42.32M
-49.57M
-35.48M
-46.82M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps